001     143436
005     20240229112553.0
024 7 _ |a 10.1182/bloodadvances.2018015966
|2 doi
024 7 _ |a pmid:30948364
|2 pmid
024 7 _ |a pmc:PMC6457221
|2 pmc
024 7 _ |a 2473-9529
|2 ISSN
024 7 _ |a 2473-9537
|2 ISSN
024 7 _ |a 2476-9537
|2 ISSN
024 7 _ |a altmetric:58644767
|2 altmetric
037 _ _ |a DKFZ-2019-01024
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Costa, Barbara Maria
|0 P:(DE-He78)2fe44044f40217387daaf299f2eb7340
|b 0
|e First author
|u dkfz
245 _ _ |a Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells.
260 _ _ |a Washington, DC
|c 2019
|b American Society of Hematology
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1555309825_28575
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a DKFZ-ZMBH Alliance
520 _ _ |a Binding of the sialomucin-like transmembrane glycoprotein podoplanin (PDPN) to the platelet receptor C-type lectin-like receptor 2 induces platelet activation and aggregation. In human high-grade gliomas, PDPN is highly expressed both in tumor cells and in tumor-associated astrocytes. In glioma patients, high expression of PDPN is associated with worse prognosis and has been shown to correlate with intratumoral platelet aggregation and an increased risk of venous thromboembolism (VTE). To functionally assess the role of PDPN in platelet aggregation in vivo, we established a syngeneic orthotopic murine glioma model in C57/Bl6 mice, based on transplantation of p53- and Pten-deficient neural stem cells. This model is characterized by the presence of intratumoral platelet aggregates and by the upregulation of PDPN both in glioma cells and in astrocytes, reflecting the characteristics of human gliomas. Deletion of PDPN either in tumor cells or in astrocytes resulted in glioma formation with similar penetrance and grade compared with control mice. Importantly, only the lack of PDPN in tumor cells, but not in astrocytes, caused a significant reduction in intratumoral platelet aggregates, whereas in vitro, both cell types have similar platelet aggregation-inducing capacities. Our results demonstrate a causative link between PDPN and platelet aggregation in gliomas and pinpoint the tumor cells as the major players in PDPN-induced platelet aggregation. Our data indicate that blocking PDPN specifically on tumor cells could represent a novel strategy to prevent platelet aggregation and thereby reduce the risk of VTE in glioma patients.
536 _ _ |a 311 - Signalling pathways, cell and tumor biology (POF3-311)
|0 G:(DE-HGF)POF3-311
|c POF3-311
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Eisemann, Tanja
|0 P:(DE-He78)db396aa5e7017ae96520ba81ded5fc0e
|b 1
|u dkfz
700 1 _ |a Strelau, Jens
|b 2
700 1 _ |a Spaan, Ingrid
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 4
|u dkfz
700 1 _ |a Liu, Hai-Kun
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Bugert, Peter
|b 6
700 1 _ |a Angel, Peter
|0 P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9
|b 7
|u dkfz
700 1 _ |a Peterziel, Heike
|0 P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e
|b 8
|e Last author
|u dkfz
773 _ _ |a 10.1182/bloodadvances.2018015966
|g Vol. 3, no. 7, p. 1092 - 1102
|0 PERI:(DE-600)2876449-3
|n 7
|p 1092 - 1102
|t Blood advances
|v 3
|y 2019
|x 2473-9537
909 C O |o oai:inrepo02.dkfz.de:143436
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)2fe44044f40217387daaf299f2eb7340
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)db396aa5e7017ae96520ba81ded5fc0e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-311
|2 G:(DE-HGF)POF3-300
|v Signalling pathways, cell and tumor biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
920 1 _ |0 I:(DE-He78)A100-20160331
|k A100
|l Signaltransduktion/Wachstumskontrolle
|x 0
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 1
920 1 _ |0 I:(DE-He78)A240-20160331
|k A240
|l Molekulare Neurogenetik
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A100-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a I:(DE-He78)A240-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21